Companies news
Astek Group acquires the Life Sciences CRO activities of the Keyrus Group
Levallois-Perret (France) - June 23, 2025: The Keyrus Group announces that it has sold its entire Life Sciences CRO activities (IFRS 2024 consolidated revenue: €23.5m - 190 FTEs) to the Astek Group.
Keyrus, an international “Global Player” expert in Data, Artificial Intelligence and Digital, has been developing a strong value proposition in clinical research for over 25 years, in France, Belgium, Canada and the United States, covering all phases of R&D, market access and post-marketing follow-up for pharmaceutical products.
Founded in France in 1988, Astek is a global player in engineering and technology consulting, with a presence on every continent. Astek supports its international customers in the intelligent deployment of their products and services, and in the implementation of their digital transformation. The Astek Group generated consolidated revenue of €720m in 2024, 11% of which in the Life Sciences sector.
The evolution of the CRO market, its technologies and the strategies of pharmaceutical companies mean that we need to reach a critical international scale, and to have substantial offshore capacities to ensure long-term relationships with Big Pharma. With this in mind, Keyrus has decided to back its Life Sciences CRO activities with a recognized industrial player, which will enable it to continue developing in line with the market consolidation.
“Through this operation, our group is refocusing its efforts and investments on its core Data & AI business, which requires organic resources in terms of innovation and development of new technological partnerships, and intends to participate in the consolidation of the market through external growth”, declares Eric Cohen, Founder and Chairman of the Keyrus Group.
"We chose the Astek Group to offer our teams the best future, both in terms of industrial vision and in terms of culture and values very similar to those of the Keyrus Group. Keyrus' Life Sciences CRO activities will henceforth be called Alsinova, and will continue to develop within the Astek Group. The know-how and quality of service we have developed over more than 25 years will be major assets for Astek's future projects", adds Marc Stukkens, CEO of the Keyrus Group.
Julien Gavaldon, Chairman of the Management Board of Groupe Astek, comments: "The planned acquisition of Keyrus' Life Sciences CRO activities illustrates our commitment to becoming a key player in the digital transformation of Life Sciences. By combining our engineering and data science skills with the expertise of Keyrus' CRO activities, we are ideally positioned to support our customers in their clinical, regulatory and technological challenges on a global scale".
SOURCE: Keyrus
